Trelegy ellipta and Back disorder - a phase IV clinical study of FDA data

Summary:

Back disorder is reported as a side effect among people who take Trelegy ellipta (fluticasone furoate; umeclidinium bromide; vilanterol trifenatate), especially for people who are female, 60+ old, also take Gabapentin, and have Idiopathic pulmonary fibrosis.

The phase IV clinical study analyzes which people have Back disorder when taking Trelegy ellipta. It is created by eHealthMe based on reports of 27,966 people who have side effects when taking Trelegy ellipta from the FDA, and is updated regularly.

What is Trelegy ellipta?

Trelegy ellipta has active ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. eHealthMe is studying from 28,101 Trelegy ellipta users. Check the latest studies of Trelegy ellipta.

What is Back disorder?

Back disorder is found to be associated with 1,038 drugs and 1,361 conditions by eHealthMe. Check the latest studies of Back disorder.

On Jul, 11, 2026

27,966 people reported to have side effects when taking Trelegy ellipta.
Among them, 30 people (0.11%) have Back disorder.

Could Trelegy ellipta cause Back disorder?

Among these 30 people:

What is the gender of people who have Back disorder when taking Trelegy ellipta? *

female: 53.57 %
male: 46.43 %

What is the age of people who have Back disorder when taking Trelegy ellipta? *

What are other drugs people take besides Trelegy ellipta? *

What are other side effects people have besides Back disorder? *

Dyspnea (difficult or laboured breathing): 10 people, 33.33%
Pneumonia: 7 people, 23.33%
Fall: 6 people, 20.00%
Weakness: 6 people, 20.00%
Cough: 6 people, 20.00%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 5 people, 16.67%
Dizziness: 5 people, 16.67%
Drug Ineffective: 4 people, 13.33%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 13.33%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 3 people, 10.00%

What are the existing conditions these people have? *

Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 13.33%
Idiopathic Pulmonary Fibrosis (chronic lung disease): 4 people, 13.33%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 3 people, 10.00%
Immunodeficiency Common Variable: 3 people, 10.00%
Asthma: 2 people, 6.67%
Parkinson's Disease: 2 people, 6.67%
Delusion (a false belief or opinion): 2 people, 6.67%
Immune System Disorder: 2 people, 6.67%
Dyspnea (difficult or laboured breathing): 2 people, 6.67%
High Blood Cholesterol: 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Trelegy ellipta and have Back disorder?

- Check whether Back disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Trelegy ellipta:

Trelegy ellipta (28,101 reports)

Back disorder treatments and more:

Back disorder (23,781 reports)

How severe was Back disorder and when was it recovered:

Back disorder in Trelegy ellipta

Expand to all the drugs that have ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate:

Back disorder and drugs with ingredients of fluticasone furoate; umeclidinium bromide; vilanterol trifenatate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Trelegy ellipta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Back disorder:

Back disorder (1,038 drugs)

Browse all the conditions that are associated with Back disorder:

Back disorder (1,361 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fluticasone furoate; umeclidinium bromide; vilanterol trifenatate (the active ingredients of Trelegy ellipta) and Trelegy ellipta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.